m+Medelevator.RU
← Поиск публикаций
Nature immunology · 2025

A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Andrade Augusto Faria, Sigaud Romain, Puligandla Evan, Liu Bridget, Karimi Elham, Annett Alva, Rezanejad Morteza, Jawhar Wajih, Taylor Robert, Cao Yi, Schmid Simone, Selt Florian, Hernáiz Driever Pablo, Horn Svea, Sievers Philipp, Prinz Marco, Glatzel Markus, Mawrin Christian, Hartmann Christian, Monoranu Camelia-Maria, Konnikova Liza, Sahm Felix, Pfister Stefan M, Witt Olaf, Jones David T W, Koch Arend, Kleinman Claudia L, Capper David, Walsh Logan, Jabado Nada, Milde Till

Аннотация

Pediatric low-grade gliomas (pLGGs) are mitogen-activated protein kinase (MAPK) pathway-activated brain tumors prevalent in children and are associated with morbidity despite favorable survival. Here using imaging mass cytometry, we spatially characterized at the single-cell level the tumor microenvironment (TME) of 120 pLGG cases, considering age, molecular drivers, brain location and tumor subtype. Our analysis identified myeloid cells-including resident microglia and bone marrow-derived macrophages-as the predominant immune population in the TME, particularly in optic pathway tumors. Additionally, we discovered an immune signature predictive of progression-free survival. Spatial analysis identified specific cellular interactions, notably myeloid-myeloid contacts and macrophage-enriched regions harboring MAPK-activated, TIM-3+ myeloid cells, suggesting an immunosuppressive TME. Our study provides a comprehensive resource on the immune landscape of these pLGGs and underscores the immunosuppressive role of diverse myeloid infiltrates. These findings also indicate that combining TIM-3 blockade with MAPK inhibition might be a promising therapeutic strategy to target both the TME and oncogenic MAPK activation in pLGG tumors.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты